Use of Systems Biology Approaches to Analysis of Genome-Wide Association Studies of Myocardial Infarction and Blood Cholesterol in the Nurses' Health Study and Health Professionals’ Follow-Up Study

With the advance of genome-wide association studies and newly identified SNP (single-nucleotide polymorphism) associations with complex disease, important discoveries have emerged focusing not only on individual genes but on disease-associated pathways and gene sets. The authors used prospective myocardial infarction case-control studies nested in the Nurses’ Health and Health Professionals Follow-Up Studies to investigate genetic variants associated with myocardial infarction or LDL, HDL, triglycerides, adiponectin and apolipoprotein B (apoB). Using these case-control studies to illustrate an integrative systems biology approach, the authors applied SNP set enrichment analysis to identify gene sets where expression SNPs representing genes from these sets show enrichment in their association with endpoints of interest. The authors also explored an aggregate score approach. While power limited one’s ability to detect significance for association of individual loci with myocardial infarction, the authors found significance for loci associated with LDL, HDL, apoB and triglycerides, replicating previous observations. Applying SNP set enrichment analysis and risk score methods, the authors also found significance for three gene sets and for aggregate scores associated with myocardial infarction as well as for loci-related to cardiovascular risk factors, supporting the use of these methods in practice.     

基于基因表达变异性的通路富集方法研究

当前的通路富集方法主要是基于基因的表达差异,很少有方法从通路变异性(方差)角度对其富集分析．我们注意到用合适的统计量描述通路的变异性时,在疾病表型下一些通路的变异性有明显的上升或者下降．因此本研究假设：通路变异性程度在不同表型中存在差异．本文设计了14种描述通路变异性的统计量与检验方法,检测不同表型下变异性有差异的通路即富集通路,并将富集结果与文献检索结果进行比较,同时,分析不同芯片预处理方法对数据和结果的影响．研究结果表明：5种预处理方法中,多阵列对数健壮算法(RMA)是数据预处理的最优方法;不同表型下通路的变异性程度存在差异;根据文献检索的通路结果,14种基于变异性的通路富集方法中,以通路中各基因欧氏距离的方差做统计量进行permutation检验(方法11)能有效识别显著通路,其富集结果优于基因集富集分析(GSEA)．综上所述,基于通路变异性的通路富集策略具有可行性,不仅对通路富集分析有一定的理论指导意义,而且为人类疾病研究提供新的视角．     

Enrichment Disequilibrium: A novel approach for measuring the degree of enrichment after gene enrichment test

Motivation: Commonly used gene enrichment analysis methods, such as Hypergeometric distribution, play an important role in the functional analysis of interesting gene lists. But the statistical significance obtained by these methods only represents the probability of error that is involved in accepting enrichment, and is not suitable to evaluate the degree of enrichment. Although there have been some methods to measure the enrichment degrees, such as relative enrichment factor, new methods are still needed to meet the requirements for comparing the degree of enrichment. Results: We developed a novel method, Enrichment Disequilibrium (ED), to measure the degree of enrichment. Enrichment equilibrium means that the interesting gene set and the known functional gene set (such as a KEGG pathway) are independent (i.e. random association). ED is defined as the degree of non-independence. Compared with the relative enrichment factor, ED has a clearer biological meaning, is a standardized indicator, and has a symmetrical interval (range from -1 to +1). It is more suitable to measure the enrichment degree. For an interesting gene set, researchers can obtain some significant functional gene sets by traditional enrichment test. Then using ED, they can compare the degree of enrichment among these significant gene sets, and prioritize them.     

The DrugPattern tool for drug set enrichment analysis and its prediction for beneficial effects of oxLDL on type 2 diabetes

Enrichment analysis methods, e.g., gene set enrichment analysis, represent one class of important bioinformatical resources for mining patterns in biomedical datasets. However, tools for inferring patterns and rules of a list of drugs are limited. In this study, we developed a web-based tool, DrugPattern, for drug set enrichment analysis. We first collected and curated 7019 drug sets, including indications, adverse reactions, targets, pathways, etc. from public databases. For a list of interested drugs, DrugPattern then evaluates the significance of the enrichment of these drugs in each of the 7019 drug sets. To validate DrugPattern, we employed it for the prediction of the effects of oxidized low-density lipoprotein (oxLDL), a factor expected to be deleterious. We predicted that oxLDL has beneficial effects on some diseases, most of which were supported by evidence in the literature. Because DrugPattern predicted the potential beneficial effects of oxLDL in type 2 diabetes (T2D), animal experiments were then performed to further verify this prediction. As a result, the experimental evidences validated the DrugPattern prediction that oxLDL indeed has beneficial effects on T2D in the case of energy restriction. These data confirmed the prediction accuracy of our approach and revealed unexpected protective roles for oxLDL in various diseases. This study provides a tool to infer patterns and rules in biomedical datasets based on drug set enrichment analysis. DrugPattern is available at http://www.cuilab.cn/drugpattern.     

Appearance frequency modulated gene set enrichment testing

Background  

Gene set enrichment testing has helped bridge the gap from an individual gene to a systems biology interpretation of microarray data. Although gene sets are defined a priori based on biological knowledge, current methods for gene set enrichment testing treat all genes equal. It is well-known that some genes, such as those responsible for housekeeping functions, appear in many pathways, whereas other genes are more specialized and play a unique role in a single pathway. Drawing inspiration from the field of information retrieval, we have developed and present here an approach to incorporate gene appearance frequency (in KEGG pathways) into two current methods, Gene Set Enrichment Analysis (GSEA) and logistic regression-based LRpath framework, to generate more reproducible and biologically meaningful results.     

Patient-oriented gene set analysis for cancer mutation data

Recent research has revealed complex heterogeneous genomic landscapes in human cancers. However, mutations tend to occur within a core group of pathways and biological processes that can be grouped into gene sets. To better understand the significance of these pathways, we have developed an approach that initially scores each gene set at the patient rather than the gene level. In mutation analysis, these patient-oriented methods are more transparent, interpretable, and statistically powerful than traditional gene-oriented methods.     

Advanced significance analysis of microarray data based on weighted resampling: a comparative study and application to gene deletions in Mycobacterium bovis

MOTIVATION: When analyzing microarray data, non-biological variation introduces uncertainty in the analysis and interpretation. In this paper we focus on the validation of significant differences in gene expression levels, or normalized channel intensity levels with respect to different experimental conditions and with replicated measurements. A myriad of methods have been proposed to study differences in gene expression levels and to assign significance values as a measure of confidence. In this paper we compare several methods, including SAM, regularized t-test, mixture modeling, Wilk's lambda score and variance stabilization. From this comparison we developed a weighted resampling approach and applied it to gene deletions in Mycobacterium bovis. RESULTS: We discuss the assumptions, model structure, computational complexity and applicability to microarray data. The results of our study justified the theoretical basis of the weighted resampling approach, which clearly outperforms the others.     

Testing gene set enrichment for subset of genes: Sub-GSE

Background  

Many methods have been developed to test the enrichment of genes related to certain phenotypes or cell states in gene sets. These approaches usually combine gene expression data with functionally related gene sets as defined in databases such as GeneOntology (GO), KEGG, or BioCarta. The results based on gene set analysis are generally more biologically interpretable, accurate and robust than the results based on individual gene analysis. However, while most available methods for gene set enrichment analysis test the enrichment of the entire gene set, it is more likely that only a subset of the genes in the gene set may be related to the phenotypes of interest.     

Bayesian Joint Analysis of Gene Expression Data and Gene Functional Annotations

Identifying which genes and which gene sets are differentially expressed (DE) under two experimental conditions are both key questions in microarray analysis. Although closely related and seemingly similar, they cannot replace each other, due to their own importance and merits in scientific discoveries. Existing approaches have been developed to address only one of the two questions. Further, most of the methods for detecting DE genes purely rely on gene expression analysis, without using the information about gene functional grouping. Methods for detecting altered gene sets often use a two-step procedure, of which the first step conducts differential expression analysis using expression data only, and the second step takes results from the first step and tries to examine whether each predefined gene set is overrepresented by DE genes through some testing procedure. Such a sequential manner in analysis might cause information loss by just focusing on summary results without using the entire expression data in the second step. Here, we propose a Bayesian joint modeling approach to address the two key questions in parallel, which incorporates the information of functional annotations into expression data analysis and meanwhile infer the enrichment of functional groups. Simulation results and analysis of experimental data obtained for E.?coli show improved statistical power of our integrated approach in both identifying DE genes and altered gene sets, when compared to conventional methods.     

CBEA: Competitive balances for taxonomic enrichment analysis

Research in human-associated microbiomes often involves the analysis of taxonomic count tables generated via high-throughput sequencing. It is difficult to apply statistical tools as the data is high-dimensional, sparse, and compositional. An approachable way to alleviate high-dimensionality and sparsity is to aggregate variables into pre-defined sets. Set-based analysis is ubiquitous in the genomics literature and has demonstrable impact on improving interpretability and power of downstream analysis. Unfortunately, there is a lack of sophisticated set-based analysis methods specific to microbiome taxonomic data, where current practice often employs abundance summation as a technique for aggregation. This approach prevents comparison across sets of different sizes, does not preserve inter-sample distances, and amplifies protocol bias. Here, we attempt to fill this gap with a new single-sample taxon enrichment method that uses a novel log-ratio formulation based on the competitive null hypothesis commonly used in the enrichment analysis literature. Our approach, titled competitive balances for taxonomic enrichment analysis (CBEA), generates sample-specific enrichment scores as the scaled log-ratio of the subcomposition defined by taxa within a set and the subcomposition defined by its complement. We provide sample-level significance testing by estimating an empirical null distribution of our test statistic with valid p-values. Herein, we demonstrate, using both real data applications and simulations, that CBEA controls for type I error, even under high sparsity and high inter-taxa correlation scenarios. Additionally, CBEA provides informative scores that can be inputs to downstream analyses such as prediction tasks.     

Chapter 9: Analyses Using Disease Ontologies

Advanced statistical methods used to analyze high-throughput data such as gene-expression assays result in long lists of “significant genes.” One way to gain insight into the significance of altered expression levels is to determine whether Gene Ontology (GO) terms associated with a particular biological process, molecular function, or cellular component are over- or under-represented in the set of genes deemed significant. This process, referred to as enrichment analysis, profiles a gene-set, and is widely used to makes sense of the results of high-throughput experiments. The canonical example of enrichment analysis is when the output dataset is a list of genes differentially expressed in some condition. To determine the biological relevance of a lengthy gene list, the usual solution is to perform enrichment analysis with the GO. We can aggregate the annotating GO concepts for each gene in this list, and arrive at a profile of the biological processes or mechanisms affected by the condition under study. While GO has been the principal target for enrichment analysis, the methods of enrichment analysis are generalizable. We can conduct the same sort of profiling along other ontologies of interest. Just as scientists can ask “Which biological process is over-represented in my set of interesting genes or proteins?” we can also ask “Which disease (or class of diseases) is over-represented in my set of interesting genes or proteins?“. For example, by annotating known protein mutations with disease terms from the ontologies in BioPortal, Mort et al. recently identified a class of diseases—blood coagulation disorders—that were associated with a 14-fold depletion in substitutions at O-linked glycosylation sites. With the availability of tools for automatic annotation of datasets with terms from disease ontologies, there is no reason to restrict enrichment analyses to the GO. In this chapter, we will discuss methods to perform enrichment analysis using any ontology available in the biomedical domain. We will review the general methodology of enrichment analysis, the associated challenges, and discuss the novel translational analyses enabled by the existence of public, national computational infrastructure and by the use of disease ontologies in such analyses.

What to Learn in This Chapter

• Review the commonly used approach of Gene Ontology based enrichment analysis
• Understand the pitfalls associated with current approaches
• Understand the national infrastructure available for using alternative ontologies for enrichment analysis
• Learn about a generalized enrichment analysis workflow and its application using disease ontologies

This article is part of the “Translational Bioinformatics” collection for PLOS Computational Biology.

     

全基因组关联研究通路分析方法现状

全基因组关联研究(genome-wide association study, GWAS)自2005年首次发表以来已不断增进人们对疾病遗传机制的认识,结合系统生物学并改进统计分析方法是对GWAS数据进行深度挖掘的重要途径。通路分析(pathway analysis)将GWAS所检测的遗传变异根据一定的生物学含义组合为集合进行分析,有利于发现对疾病单独效应小却在通路中相互关联的遗传变异,更有利于进行生物学解释。当前通路分析在GWAS数据上已有较为广泛的应用并取得初步成果。与此同时,通路分析的统计方法仍在不断发展。本文旨在介绍现有直接以SNP为对象的GWAS通路分析算法,根据方法中是否采用核函数分为非核算法和核算法两大类,其中非核算法主要包括基因功能富集分析(gene set enrichment analysis, GSEA)和分层贝叶斯优取(hierarchical Bayes prioritization, HBP),核算法包括线性核(linear kernel, LIN)、状态认证核(identity-by-status kernel, IBS)和尺度不变核(powered exponential kernel)。通过介绍这些方法的计算原理和优缺点,以期为新算法的构建提供更好的思路,为GWAS领域研究方法的选择提供参考。     

Optimizing gene set annotations combining GO structure and gene expression data

Background

With the rapid accumulation of genomic data, it has become a challenge issue to annotate and interpret these data. As a representative, Gene set enrichment analysis has been widely used to interpret large molecular datasets generated by biological experiments. The result of gene set enrichment analysis heavily relies on the quality and integrity of gene set annotations. Although several methods were developed to annotate gene sets, there is still a lack of high quality annotation methods. Here, we propose a novel method to improve the annotation accuracy through combining the GO structure and gene expression data.

Results

We propose a novel approach for optimizing gene set annotations to get more accurate annotation results. The proposed method filters the inconsistent annotations using GO structure information and probabilistic gene set clusters calculated by a range of cluster sizes over multiple bootstrap resampled datasets. The proposed method is employed to analyze p53 cell lines, colon cancer and breast cancer gene expression data. The experimental results show that the proposed method can filter a number of annotations unrelated to experimental data and increase gene set enrichment power and decrease the inconsistent of annotations.

Conclusions

A novel gene set annotation optimization approach is proposed to improve the quality of gene annotations. Experimental results indicate that the proposed method effectively improves gene set annotation quality based on the GO structure and gene expression data.

     

Extending pathways based on gene lists using InterPro domain signatures

Background

High-throughput technologies like functional screens and gene expression analysis produce extended lists of candidate genes. Gene-Set Enrichment Analysis is a commonly used and well established technique to test for the statistically significant over-representation of particular pathways. A shortcoming of this method is however, that most genes that are investigated in the experiments have very sparse functional or pathway annotation and therefore cannot be the target of such an analysis. The approach presented here aims to assign lists of genes with limited annotation to previously described functional gene collections or pathways. This works by comparing InterPro domain signatures of the candidate gene lists with domain signatures of gene sets derived from known classifications, e.g. KEGG pathways.

Results

In order to validate our approach, we designed a simulation study. Based on all pathways available in the KEGG database, we create test gene lists by randomly selecting pathway genes, removing these genes from the known pathways and adding variable amounts of noise in the form of genes not annotated to the pathway. We show that we can recover pathway memberships based on the simulated gene lists with high accuracy. We further demonstrate the applicability of our approach on a biological example.

Conclusion

Results based on simulation and data analysis show that domain based pathway enrichment analysis is a very sensitive method to test for enrichment of pathways in sparsely annotated lists of genes. An R based software package domainsignatures, to routinely perform this analysis on the results of high-throughput screening, is available via Bioconductor.     

基因表达谱富集分析方法研究进展

微阵列技术是生物技术变革的核心,允许研究者同时监测成千上万个基因的表达水平,已广泛应用于医学研究。如何挖掘海量基因表达信息中的有用信息并进行生物学专业解释,是基因表达谱数据分析领域所面临的一个重要挑战。不同的研究者提出了各种基于基因集进行富集分析的方法,在此将这些方法大致分为两大类,即bottom-up方法和top-down方法。前者先进行单基因分析,然后根据生物学领域知识注释基因集并进行分析。该方法应用广泛,且结果比单基因分析容易解释。后者先根据生物学领域知识将各基因进行归类,然后进行基因差异表达模式分析。该方法不仅能提高结论的可解释性,而且能达到降维的目的。     

Urgent need for consistent standards in functional enrichment analysis

Gene set enrichment tests (a.k.a. functional enrichment analysis) are among the most frequently used methods in computational biology. Despite this popularity, there are concerns that these methods are being applied incorrectly and the results of some peer-reviewed publications are unreliable. These problems include the use of inappropriate background gene lists, lack of false discovery rate correction and lack of methodological detail. To ascertain the frequency of these issues in the literature, we performed a screen of 186 open-access research articles describing functional enrichment results. We find that 95% of analyses using over-representation tests did not implement an appropriate background gene list or did not describe this in the methods. Failure to perform p-value correction for multiple tests was identified in 43% of analyses. Many studies lacked detail in the methods section about the tools and gene sets used. An extension of this survey showed that these problems are not associated with journal or article level bibliometrics. Using seven independent RNA-seq datasets, we show misuse of enrichment tools alters results substantially. In conclusion, most published functional enrichment studies suffered from one or more major flaws, highlighting the need for stronger standards for enrichment analysis.     

Functional enrichment analysis with structural variants: pitfalls and strategies

Interpreting the phenotypic consequences of human structural variation remains challenging. Functional enrichment analysis, which can identify functional enrichments among genes affected by structural variants, is providing significant biological insights into the genotype-phenotype relationship. In this review, we discuss the different approaches and choices in the application of this technique to human structural variation. We consider the importance of choosing the right background distribution for detection, the significance of the gene selection criteria, the effects of tissue-specific gene length biases and discuss sources of functional annotations with a focus on Gene Ontology and mouse phenotypic resources. Throughout this review, we highlight potential sources of significant bias that are of particular concern to the analysis of structural variants, and illustrate the importance of examining the expectations upon which enrichment analysis techniques depend.